Cardiomyopathy - Related Links
Open Access Articles- Top Results for Cardiomyopathy
Journal of Obesity & Weight Loss TherapyA Short Literature Review on Diabetic Cardiomyopathy in Obese Conditions
Journal of Clinical & Experimental CardiologyTakotsubo Cardiomyopathy a Case Report: Ballooning outside the Apex?
Journal of Clinical & Experimental CardiologyCurcumin Attenuates Doxorubicin-Induced Cardiotoxicity by Inducing Autophagy via the Regulation of JNK Phosphorylation
Journal of Stem Cell Research & TherapyEndogenous Laser Induced Ventricular Enhancement (ELIVE) Therapy: A New Paradigm for Treating Heart Failure?
Gynecology & ObstetricsAcute Management of Cardiac Complications in Pregnancy
File:Idiopathic cardiomyopathy, gross pathology 20G0018 lores.jpg|
Opened left ventricle of heart shows a thickened, dilated left ventricle with subendocardial fibrosis manifested as increased whiteness of endocardium.
|Classification and external resources|
Cardiomyopathy (literally "heart muscle disease") is the measurable deterioration for any reason of the ability of the myocardium (the heart muscle) to contract, usually leading to heart failure. Common symptoms include dyspnea (breathlessness) and peripheral edema (swelling of the legs). Those with cardiomyopathy are often at risk of dangerous forms of irregular heart rate and sudden cardiac death. The most common form of cardiomyopathy is dilated cardiomyopathy. Although the term "cardiomyopathy" could theoretically apply to almost any disease affecting the heart, it is usually reserved for "severe myocardial disease leading to heart failure".
The term 'cardiomyopathy' only came into use about 50 years ago. The definition has advanced as knowledge has increased and new diagnostic tests have been introduced. In 2008, the European Society of Cardiology defined it as a myocardial disorder in which the heart muscle was structurally abnormal and functioned abnormally.   Two years earlier, the American Heart Association had pointed out that cardiomyopathies were either confined to the heart or were part of a generalized disorder, both often leading to death or progressive heart failure. Both groups excluded heart disease due to coronary artery disease, hypertension, abnormalities of the heart valves, and heart disease present at birth from the definition. Earlier, simpler, categories such as intrinsic, (defined as weakness of the heart muscle without an identifiable external cause), and extrinsic, (where the primary pathology arose outside the myocardium itself), became more difficult to sustain. For example, as more external causes were recognized, the intrinsic category became smaller. Alcoholism, for example, has been identified as a cause of dilated cardiomyopathy, as has drug toxicity, and certain infections (including Hepatitis C). On the other hand, molecular biology and genetics have given rise to the recognition of various genetic causes, increasing the intrinsic category. For example, mutations in the cardiac desmosomal genes as well as in the DES gene may cause arrhythmogenic right ventricular cardiomyopathy (ARVC).
At the same time, a more clinical categorization of cardiomyopathy as 'hypertrophied', 'dilated', or 'restrictive', became difficult to maintain when it became apparent that some of the conditions could fulfill more than one of those three categories at any particular stage of their development.
The current American Heart Association definition divides cardiomyopathies into primary, which affect the heart alone, and secondary, which are the result of illness affecting other parts of the body. These categories are further broken down into subgroups which incorporate new genetic and molecular biology knowledge.
- Primary/intrinsic cardiomyopathies
- Secondary/extrinsic cardiomyopathies
- Nutritional diseases
Signs and symptoms
Symptoms and signs may mimic those of almost any form of heart disease. Chest pain is common. Mild myocarditis or cardiomyopathy is frequently asymptomatic; severe cases are associated with heart failure, arrhythmias, and systemic embolization. Manifestations of the underlying disease (e.g., Chagas' disease) may be prominent. Most patients with biopsy-proven myocarditis report a recent viral prodrome preceding cardiovascular symptoms.
ECG abnormalities are often present, although the changes are frequently nonspecific. A pattern characteristic of left ventricular hypertrophy may be present. Flat or inverted T waves are most common, often with low-voltage QRS complexes. Intraventricular conduction defects and bundle branch block, especially left bundle branch block, are also common. An echocardiogram is useful to detect wall motion abnormalities or a pericardial effusion. Chest radiographs can be normal or can show evidence of congestive heart failure with pulmonary edema or cardiomegaly.
Treatment depends on the type of cardiomyopathy and condition of disease, but may include medication (conservative treatment) or iatrogenic/implanted pacemakers for slow heart rates, defibrillators for those prone to fatal heart rhythms, ventricular assist devices (VADs) for severe heart failure, or ablation for recurring dysrhythmias that cannot be eliminated by medication or mechanical cardioversion. The goal of treatment is often symptom relief, and some patients may eventually require a heart transplant. Treatment of cardiomyopathy (and other heart diseases) using alternative methods such as stem cell therapy is commercially available but is not supported by convincing evidence.
- Kasper, Denis Lh. et al. (2005). Harrison's Principles of Internal Medicine, 16th edn. McGraw-Hill. ISBN 0-07-139140-1.
- Cardiopulmonary Pharmacology for Respiratory Care, Jahangir Moini, Ch.2; page 24
- Gabriel A. Adelmann; McKenna, W; Bristow, M; Maisch, B; Mautner, B; O'Connell, J; Olsen, E; Thiene, G et al. (1996). Cardiology Essentials in Clinical Practice. Circulation 93 (5). pp. 841–2. ISBN 9781849963053. PMID 8598070. doi:10.1161/01.CIR.93.5.841. Retrieved 11he 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Check date values in:
|accessdate=(help) (Full text)
- GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. PMID 25530442. doi:10.1016/S0140-6736(14)61682-2.
- "Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies". Br Heart J 44 (6): 672–3. Dec 1980. PMC 482464. PMID 7459150. doi:10.1136/hrt.44.6.672.
- Abelmann WH (Sep–Oct 1984). "Classification and natural history of primary myocardial disease". Prog Cardiovasc Dis 27 (2): 73–94. PMID 6382439. doi:10.1016/0033-0620(84)90020-3.
- Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (Mar 1996). "Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies". Circulation 93 (5): 841–2. PMID 8598070. doi:10.1161/01.CIR.93.5.841.
- Klauke B, Kossmann S, Gaertner A, Brand K, Stork I, Brodehl A, Dieding M, Walhorn V, Anselmetti D, Gerdes D, Bohms B, Schulz U, Zu Knyphausen E, Vorgerd M, Gummert J, Milting H (2010). "De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy". Hum. Mol. Genet. 19 (23): 4595–607. PMID 20829228. doi:10.1093/hmg/ddq387.
- Brodehl A, Hedde PN, Dieding M, Fatima A, Walhorn V, Gayda S, Šarić T, Klauke B, Gummert J, Anselmetti D, Heilemann M, Nienhaus GU, Milting H (2012). "Dual color photoactivation localization microscopy of cardiomyopathy-associated desmin mutants". J. Biol. Chem. 287 (19): 16047–57. PMC 3346104. PMID 22403400. doi:10.1074/jbc.M111.313841.
- Valentin Fuster; John Willis Hurst (2004). Hurst's the heart. McGraw-Hill Professional. pp. 1884–. ISBN 978-0-07-143225-2. Retrieved 11 November 2010.
- McCartan C, Maso R, Jayasinghe SR, Griffiths LR (2012). "Cardiomyopathy Classification: Ongoing Debate in the Genomics Era". Biochem Res Int. 2012 2012: 796926. PMC 3423823. PMID 22924131. doi:10.1155/2012/796926.
- Improvement in Hypertrophic Cardiomyopathy; http://www.medscape.com/viewarticle/457562_4
- Elliott, P.; Andersson, B.; Arbustini, E.; Bilinska, Z.; Cecchi, F.; Charron, P.; Dubourg, O.; Kühl, U.; Maisch, B.; McKenna, W. J.; Monserrat, L.; Pankuweit, S.; Rapezzi, C.; Seferovic, P.; Tavazzi, L.; Keren, A. (2007). "Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases". European Heart Journal 29 (2): 270–276. PMID 17916581. doi:10.1093/eurheartj/ehm342.
- Maron, B. J.; Towbin, J. A.; Thiene, G.; Antzelevitch, C.; Corrado, D.; Arnett, D.; Moss, A. J.; Seidman, C. E.; Young, J. B.; American Heart, A. (2006). "Contemporary Definitions and Classification of the Cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention". Circulation 113 (14): 1807–1816. PMID 16567565. doi:10.1161/CIRCULATIONAHA.106.174287.
- Cardiomyopathy at DMOZ
- Cardiomyopathy information for parents.
-  The CMA information on cardiomyopathy